Overview

Hypertension and Cardiovascular Risk Factors

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Hydrochlorothiazide
Valsartan